World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
119
Citations
74630
World Ranking
337
National Ranking
212

Medicine

D-Index
121
Citations
75458
World Ranking
3544
National Ranking
1952

Michel Sadelain publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Michel Sadelain sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 69 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 538 publications — 92nd percentile

92% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Michel Sadelain D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Michel Sadelain sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 163 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 119 D-Index — 93rd percentile

93% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Michel Sadelain is affiliated with Columbia University in the United States, focusing on research in medicine, immunology, and molecular biology. Their work spans several important subfields, including oncology, immunology, molecular biology, electrical and electronic engineering, and genetics.

The core of their research revolves around CAR-T cell therapy, a specialized form of immunotherapy involving genetically engineered T cells designed to target cancer cells. This area is prominently represented with 196 publications, alongside studies on immune cell function and interaction, viral infectious diseases, gene expression in insects, immunotherapy, immune responses, CRISPR and genetic engineering, as well as advancements in semiconductor devices, circuit design, biosimilars, and bioanalytical methods.

Michel Sadelain has contributed notably to various research publications, including the following recent papers:

  • Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer, 2023, Nature
  • Senolytic CAR T cells reverse senescence-associated pathologies, 2020, Nature
  • Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy, 2021, Nature Reviews Immunology
  • A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab, 2021, Cancer Discovery
  • Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy, 2022, Nature Medicine

Their frequent co-authors consist of researchers with whom they have collaborated extensively:

  • Isabelle Rivière (41 publications)
  • Jorge Mansilla-Soto (32 publications)
  • Jae H. Park (26 publications)
  • Renier J. Brentjens (22 publications)
  • Judith Feucht (20 publications)

Michel Sadelain's work appears regularly in several leading publication venues. Those include:

  • Blood (25 publications)
  • Cancer Research (9 publications)
  • Nature Medicine (7 publications)
  • bioRxiv (Cold Spring Harbor Laboratory) (7 publications)
  • Nature (6 publications)

Best Publications

  • Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling

    Stuart M Chambers;Christopher A. Fasano;Eirini P. Papapetrou;Mark J. Tomishima

  • Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

    Marco L. Davila;Isabelle Riviere;Xiuyan Wang;Shirley Bartido

  • Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

    Jae H. Park;Isabelle Rivière;Mithat Gonen;Xiuyan Wang

  • Chimeric Antigen Receptor Therapy.

    Carl H. June;Michel Sadelain

  • CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia

    Renier J. Brentjens;Marco L. Davila;Isabelle Riviere;Jae Park

  • The Basic Principles of Chimeric Antigen Receptor Design

    Michel Sadelain;Renier Brentjens;Isabelle Rivière

  • Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection

    Justin Eyquem;Jorge Mansilla-Soto;Theodoros Giavridis;Sjoukje J. C. van der Stegen

  • Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

    Renier J. Brentjens;Isabelle Rivière;Jae H. Park;Marco L. Davila

  • Gene therapy comes of age.

    Cynthia E. Dunbar;Katherine A. High;J. Keith Joung;Donald B. Kohn

  • Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer

    Unknown

  • Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor.

    John Maher;Renier J Brentjens;Gertrude Gunset;Isabelle Rivière

  • CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade.

    Theodoros Giavridis;Sjoukje J. C. van der Stegen;Justin Eyquem;Mohamad Hamieh

  • Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs

    Gabsang Lee;Eirini P. Papapetrou;Hyesoo Kim;Stuart M. Chambers

  • Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis

    Glenn Dranoff;Alexander D. Crawford;Michel Sadelain;Beverly Ream

  • Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition

    Leonid Cherkassky;Aurore Morello;Jonathan Villena-Vargas;Yang Feng

  • Therapeutic T cell engineering

    Michel Sadelain;Isabelle Rivière;Stanley Riddell

  • Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15.

    Renier J. Brentjens;Jean Baptiste Latouche;Elmer Santos;Francesc Marti

  • Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells

    Christopher C Kloss;Maud Condomines;Marc Cartellieri;Michael Bachmann

  • PD-1– and CTLA-4–Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses

    Victor D. Fedorov;Maria Themeli;Michel Sadelain

  • Senolytic CAR T cells reverse senescence-associated pathologies.

    Corina Amor;Judith Feucht;Josef Leibold;Yu-Jui Ho

  • Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning

    Hollie J. Pegram;James C. Lee;Erik G. Hayman;Gavin H. Imperato

  • The promise and potential pitfalls of chimeric antigen receptors

    Michel Sadelain;Renier Brentjens;Isabelle Rivière

Frequent Co-Authors

Isabelle Riviere
Isabelle Riviere Memorial Sloan Kettering Cancer Center
Renier J. Brentjens
Renier J. Brentjens Roswell Park Cancer Institute
Richard J. O'Reilly
Richard J. O'Reilly Memorial Sloan Kettering Cancer Center
Steven M. Larson
Steven M. Larson Memorial Sloan Kettering Cancer Center
Stefano Rivella
Stefano Rivella Children's Hospital of Philadelphia
Marcel R.M. van den Brink
Marcel R.M. van den Brink Memorial Sloan Kettering Cancer Center
Donald B. Kohn
Donald B. Kohn University of California, Los Angeles
Ronald G. Blasberg
Ronald G. Blasberg Memorial Sloan Kettering Cancer Center
Miguel-Angel Perales
Miguel-Angel Perales Memorial Sloan Kettering Cancer Center
Valerie W. Rusch
Valerie W. Rusch Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a career in Immunology often intersects with various healthcare roles, many of which benefit from advanced nursing qualifications. For those considering clinical practice, exploring acnp programs can provide specialized skills in acute care, complementing immunology knowledge with hands-on patient management expertise.

Accelerated nursing education paths such as accelerated fnp programs offer efficient routes for registered nurses to advance their credentials. These programs cater to those aiming to deepen their understanding of immunological disorders within family practice settings.

For students new to nursing or healthcare, online bsn programs for non nurses provide accessible entry points. These degrees enable individuals from diverse backgrounds to enter nursing roles connected to immunology and broader patient care.

Understanding earning potential is crucial when planning a healthcare career. Transparency in dnp salary transparency allows prospective Doctor of Nursing Practice candidates to make informed choices about their education and career development.

Best Scientists Citing Michel Sadelain

Trending Scientists

Recently Published Articles